New rhinophyma severity index and mid-term results following shave excision of rhinophyma

Dermatology. 2013;227(1):31-6. doi: 10.1159/000351556. Epub 2013 Aug 30.

Abstract

Background: Rhinophyma is a progressive nasal deformity resulting from hyperplasia of the sebaceous glands and connective tissue, with a negative effect on quality of life. Partial-thickness shave excision has been used for the treatment of rhinophyma, but the mid- and long-term efficacy of the treatment is unknown.

Objectives: We analysed the clinical outcomes of shave excision in patients with rhinophyma in our centre between 2005 and 2009.

Methods: The entire nose was shaved using a scalpel while under tumescent anaesthesia. The clinical assessment was scored using a novel Rhinophyma Severity Index.

Results: Thirty-three patients with rhinophyma and shave excision were recruited for the study. A mid-term follow-up examination was possible in 23/33 (69.7%) patients. After a mean follow-up of 37.4 ± 13.2 months, 21 (91.3%) patients showed an improved Rhinophyma Severity Index (3.3 ± 1.1 to 1.7 ± 0.9, p < 0.0001). All patients reported a high level of satisfaction after surgery (excellent or good result). Eleven (47.8%) patients developed rhinophyma recurrence.

Conclusion: Shave excision under tumescent anaesthesia is an effective treatment for rhinophyma. The treatment is associated with high patient satisfaction and minimal side effects. A possible recurrence of rhinophyma must be addressed, however, while obtaining informed consent.

MeSH terms

  • Aged
  • Amides
  • Anesthesia, Local / methods
  • Anesthetics, Local
  • Female
  • Follow-Up Studies
  • Humans
  • Lidocaine
  • Male
  • Middle Aged
  • Patient Satisfaction
  • Postoperative Hemorrhage / etiology
  • Recurrence
  • Retrospective Studies
  • Rhinophyma / surgery*
  • Ropivacaine
  • Severity of Illness Index*
  • Time Factors
  • Treatment Outcome

Substances

  • Amides
  • Anesthetics, Local
  • Ropivacaine
  • Lidocaine